Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Medtronic
Colorcon
McKesson
Baxter

Last Updated: November 30, 2021

DrugPatentWatch Database Preview

Vilazodone hydrochloride - Generic Drug Details

➤ Subscribe for complete access

« Back to Dashboard

What are the generic drug sources for vilazodone hydrochloride and what is the scope of patent protection?

Vilazodone hydrochloride is the generic ingredient in two branded drugs marketed by Allergan, Accord Hlthcare, Alembic Pharms Ltd, Invagen Pharms, and Teva Pharms Usa, and is included in five NDAs. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Vilazodone hydrochloride has sixty patent family members in twenty-nine countries.

There are fourteen drug master file entries for vilazodone hydrochloride. Two suppliers are listed for this compound. There is one tentative approval for this compound.

Recent Clinical Trials for vilazodone hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Alliance on Mental Illness
Risk Benefit Statistics LLC
National Alliance on Mental Illness New Mexico

See all vilazodone hydrochloride clinical trials

Generic filers with tentative approvals for VILAZODONE HYDROCHLORIDE
Applicant Application No. Strength Dosage Form
⤷  Free Forever Trial⤷  Free Forever Trial40MGTABLET;ORAL
⤷  Free Forever Trial⤷  Free Forever Trial10MGTABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Medical Subject Heading (MeSH) Categories for vilazodone hydrochloride
Anatomical Therapeutic Chemical (ATC) Classes for vilazodone hydrochloride
Paragraph IV (Patent) Challenges for VILAZODONE HYDROCHLORIDE
Tradename Dosage Ingredient NDA Submissiondate
VIIBRYD TABLET;ORAL vilazodone hydrochloride 022567 2015-01-21

US Patents and Regulatory Information for vilazodone hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-003 Jan 21, 2011 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Invagen Pharms VILAZODONE HYDROCHLORIDE vilazodone hydrochloride TABLET;ORAL 208200-002 Apr 7, 2021 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-003 Jan 21, 2011 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011 AB RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Teva Pharms Usa VILAZODONE HYDROCHLORIDE vilazodone hydrochloride TABLET;ORAL 208212-003 Sep 30, 2019 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011 AB RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for vilazodone hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-002 Jan 21, 2011 ⤷  Free Forever Trial ⤷  Free Forever Trial
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-003 Jan 21, 2011 ⤷  Free Forever Trial ⤷  Free Forever Trial
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011 ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
AstraZeneca
Boehringer Ingelheim
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.